drugset / Trial / NCT01129258
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blind
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04991532 following multiple (14 days) escalating oral doses in patient wtih type 2 diabetes.
Timeline
- Start
- 2010-06
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04991532 | Small molecule | 30 mg | Oral |
| Subject | PF-04991532 | Small molecule | 100 mg | Oral |
| Subject | PF-04991532 | Small molecule | 150 mg | Oral |
| Subject | PF-04991532 | Small molecule | 300 mg | Oral |
| Subject | PF-04991532 | Small molecule | 500 mg | Oral |
| Subject | PF-04991532 | Small molecule | 1000 mg | Oral |
| Subject | PF-04991532 | Small molecule | 1500 mg | Oral |